Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP Heart Disease in Breast Cancer Survivors
NCT02674204Phase 2Terminated
- Sponsor
- Cedars-Sinai Medical Center
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cardiotoxicity comparing Atorvastatin with Placebo (2 arms). Primary endpoint: Global Circumferential Strain at 12 months. Started May 2016; status: terminated.
02
Drugs
atorvastatin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT02674204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674204.